Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong
· Delayed Price · Currency is HKD 24.52
+0.42 (1.74%)
Mar 10, 2026, 9:33 AM HKT
HKG:6826 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,473 | 2,680 | 2,635 | 2,103 | 1,750 | Upgrade
|
| Revenue Growth (YoY) | -7.71% | 1.70% | 25.27% | 20.19% | 32.14% | Upgrade
|
| Cost of Revenue | - | 843.12 | 788.14 | 656.52 | 490.37 | Upgrade
|
| Gross Profit | 2,473 | 1,837 | 1,847 | 1,447 | 1,260 | Upgrade
|
| Selling, General & Admin | - | 1,228 | 1,237 | 1,085 | 898.43 | Upgrade
|
| Research & Development | - | 238.93 | 220.1 | 182.19 | 167.6 | Upgrade
|
| Other Operating Expenses | 2,253 | -2.23 | -1.97 | 15.52 | -3.18 | Upgrade
|
| Operating Expenses | 2,253 | 1,465 | 1,455 | 1,283 | 1,063 | Upgrade
|
| Operating Income | 220.5 | 372.03 | 391.79 | 164.38 | 196.9 | Upgrade
|
| Interest Expense | - | -18.06 | -7.3 | -7.6 | -4.96 | Upgrade
|
| Interest & Investment Income | - | 73.98 | 78.15 | 88.56 | 155.75 | Upgrade
|
| Earnings From Equity Investments | - | 0.99 | 0.46 | 3.51 | 2.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 19.04 | 61.88 | 44.53 | -13.3 | 32.77 | Upgrade
|
| EBT Excluding Unusual Items | 239.53 | 490.81 | 507.63 | 235.54 | 382.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.63 | 0.19 | - | Upgrade
|
| Legal Settlements | - | -27.6 | - | - | - | Upgrade
|
| Other Unusual Items | - | 2.94 | - | - | - | Upgrade
|
| Pretax Income | 239.53 | 466.15 | 508.26 | 235.73 | 382.65 | Upgrade
|
| Income Tax Expense | -11.47 | 89.9 | 95.99 | 45.4 | 35.37 | Upgrade
|
| Earnings From Continuing Operations | 251.01 | 376.24 | 412.27 | 190.33 | 347.28 | Upgrade
|
| Minority Interest in Earnings | - | 44.2 | 3.85 | -9.86 | 4.95 | Upgrade
|
| Net Income | 251.01 | 420.45 | 416.12 | 180.47 | 352.23 | Upgrade
|
| Net Income to Common | 251.01 | 420.45 | 416.12 | 180.47 | 352.23 | Upgrade
|
| Net Income Growth | -40.30% | 1.04% | 130.58% | -48.76% | 53.10% | Upgrade
|
| Shares Outstanding (Basic) | 232 | 233 | 237 | 340 | 345 | Upgrade
|
| Shares Outstanding (Diluted) | 232 | 233 | 237 | 340 | 345 | Upgrade
|
| Shares Change (YoY) | -0.30% | -1.77% | -30.24% | -1.46% | -0.62% | Upgrade
|
| EPS (Basic) | 1.08 | 1.80 | 1.75 | 0.53 | 1.02 | Upgrade
|
| EPS (Diluted) | 1.08 | 1.80 | 1.75 | 0.53 | 1.02 | Upgrade
|
| EPS Growth | -40.12% | 2.86% | 230.53% | -48.01% | 54.06% | Upgrade
|
| Free Cash Flow | - | 284.39 | 368.85 | -77.91 | 71.41 | Upgrade
|
| Free Cash Flow Per Share | - | 1.22 | 1.55 | -0.23 | 0.21 | Upgrade
|
| Dividend Per Share | - | 1.000 | 0.510 | 0.286 | 0.500 | Upgrade
|
| Dividend Growth | - | 96.00% | 78.58% | -42.86% | 40.02% | Upgrade
|
| Gross Margin | 100.00% | 68.54% | 70.09% | 68.79% | 71.98% | Upgrade
|
| Operating Margin | 8.92% | 13.88% | 14.87% | 7.81% | 11.25% | Upgrade
|
| Profit Margin | 10.15% | 15.69% | 15.79% | 8.58% | 20.13% | Upgrade
|
| Free Cash Flow Margin | - | 10.61% | 14.00% | -3.70% | 4.08% | Upgrade
|
| EBITDA | 397.53 | 549.05 | 565.26 | 343 | 332.03 | Upgrade
|
| EBITDA Margin | 16.07% | 20.49% | 21.45% | 16.31% | 18.97% | Upgrade
|
| D&A For EBITDA | 177.03 | 177.03 | 173.47 | 178.62 | 135.13 | Upgrade
|
| EBIT | 220.5 | 372.03 | 391.79 | 164.38 | 196.9 | Upgrade
|
| EBIT Margin | 8.92% | 13.88% | 14.87% | 7.81% | 11.25% | Upgrade
|
| Effective Tax Rate | - | 19.29% | 18.89% | 19.26% | 9.24% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.